Difference between revisions of "Nivolumab and relatlimab (Opdualag)"
Jump to navigation
Jump to search
m (Jwarner moved page Relatlimab (BMS-986016) to Nivolumab and relatlimab (Opdualag): FDA approval) |
|||
Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
− | From the NCI Drug Dictionary: A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. | + | From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. |
− | == | + | ==Diseases for which it is used== |
− | ===[[ | + | *[[Melanoma]] |
− | + | ||
+ | ==History of changes in FDA indication== | ||
+ | *3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic [[melanoma]]. ''(Based on RELATIVITY-047)'' | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' BMS-986016 | ||
+ | *'''Generic name:''' nivolumab and relatlimab-rmbw | ||
+ | *'''Brand name:''' Opdualag | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 10: | Line 17: | ||
[[Category:Anti-LAG-3 antibodies]] | [[Category:Anti-LAG-3 antibodies]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
− | [[Category: | + | [[Category:Combination drugs]] |
+ | [[Category:FDA approved in 2022]] |
Revision as of 21:57, 22 March 2022
Mechanism of action
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
Diseases for which it is used
History of changes in FDA indication
- 3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (Based on RELATIVITY-047)
Also known as
- Code name: BMS-986016
- Generic name: nivolumab and relatlimab-rmbw
- Brand name: Opdualag